January 5, 2009 – Genta Incorporated announced today that the Company has received notice from the U.S FDA that tesetaxel, the latest addition to Genta’s oncology product portfolio, has been granted designation as an “Orphan Drug” for treatment of patients with advanced gastric cancer.
The details can be read here.
No comments:
Post a Comment